

1/31




Figure 1

Steps in flowcytometry-based selection of phage binding to the cell surface of subpopulations of cells




Figure 2

3/31

Sort criteria for the isolation of multiple myeloma cells
based on CD38 expression
and forward/side scatter pattern




Figure 3

Staining of blood, spleen, tonsil, multiple myeloma (MMBM) and adult bone marrow (ABM) with a control phage (upper row) or with K53 (lower row).





Figure 4

5/31

VH and VL gene utilization and deduced amino acid sequence
of the CDR3 regions of K19, K29 and K53

<u>scFv</u>	<u>CDR3</u>	<u>VH*</u>	<u>VL</u>
K19:	DYRYPSTSWFDS	DP31	V _K 3
K29:	ARRWAAFDY	DP44/45	V _K 2
K53:	GMMRGVFDY	DP14	V _K 2

Figure 5

[illegible][illegible]

Staining of insect cells transfected with a human placenta cDNA
library with K19 antibody after subsequent rounds of flowcytometric
isolation




Figure 7

Human monoclonal antibodies K19 and K53 detect glycosylation variants of CD46




Figure 8

9/31




FIGURE 9

10/31

Tumor cell killing with with human monoclonal antibodies using a
xenograft model of colon carcinoma






Figure 10



11/31

STAINING BONE MARROW OF MULTIPLE MYELOMA PATIENTS PRIMARY TUMORS

P1 (FRESH)



P2 (N2)



P4 (N2)







Figure 11A



12/31

STAINING BONE MARROW OF MULTIPLE MYELOMA PATIENTS RESPONSIVE TUMORS

P11 (FRESH)



P5 (N2)



P7 (N2)







Figure 11B



13/31

STAINING BONE MARROW OF MULTIPLE MYELOMA PATIENTS REFRACTORY TUMORS

P8 (FRESH)



P10 (FRESH)



P13 (FRESH)







Figure 11C

T04280" 98E07660



14/31

STAINING BONE MARROW OF MULTIPLE MYELOMA PATIENTS REFRACTORY TUMORS

P3 (N2)



P6 (N2)



P9 (N2)







Figure 11D

15/31

STAINING BONE MARROW OF MULTIPLE MYELOMA PATIENTS REFRACTORY TUMORS

P12 (N2)



P8 (N2)

(FROM ABOUT ONE YEAR BEFORE THE FRESH MATERIAL)







Figure 11E

16/31

STAINING BONE MARROW OF PATIENTS WITH OTHER LEUKEMIC TUMORS

A1 (T-ALL)

GATE FOR TUMOR CELLS : CD45-



A9 (B-NHL)

GATE FOR TUMOR CELLS : CD20+







Figure 12A

17/31

STAINING BONE MARROW OF PATIENTS WITH OTHER LEUKEMIC TUMORS

A4 (M0/M1 MYELOID)

GATE FOR TUMORCELLS : CD45 WEAK



A5 (M4 MYELOID)

GATE FOR TUMORCELLS : CD45+





Figure 12B

STAINING BONE MARROW OF PATIENTS WITH OTHER LEUKEMIC TUMORS

A7 (CLL)

GATE FOR TUMOR CELLS : CD19+







Figure 12C

19/31

STAINING OF NORMAL TISSUES

NORMAL BONE MARROW



TONSIL







Figure 13



20/31

STAINING OF NORMAL BLOOD

MONOCYTES



T-CELLS



B-CELLS





Figure 14

FIG. 14: Staining of Normal Blood

21/31

Specific staining of human colon tumor tissue with
Anti-CD46 monoclonal antibody K53/IgG1





Figure 15

Figure 16



23/31




Figure 17

24/31

Group A (Ab treatment at day 1, 3 and 6)




Figure 18

Group B (Ab treatment at day 6, 9 and 12)
n=10




Figure 19

25 / 31

Group C (Ab treatment at day 9, 12 and 15)
n=10




Figure 20

Group A (Ab treatment at day 1, 3 and 6)
tumor bearing mice




Figure 21

Group B (Ab treatment at day 6, 9 and 12)
tumor bearing mice




Figure 22

Group C (Ab treatment at day 9, 12 and 15)
tumor bearing mice




Figure 23

27/31

FIG. 24





Figure 24

Figure 25



29/31




Figure 26

30/31




Figure 27

31/31

Figure 28

